["{\n\"step_by_step_thinking\": \"The relevant documents provide information on various regimens for non-small cell lung cancer (NSCLC). The document [Randomized trial of cisplatin plus ifosfamide versus cisplatin plus vindesine for non-small cell lung cancer (NSCLC)] compares the efficacy of two regimens, but does not mention Figitumumab. Another document, [Phase II study of ifosfamide, cisplatin, and vindesine combination in advanced non-small cell lung cancer], discusses a 3-drug combination for NSCLC treatment. However, it too does not involve Figitumumab. No other relevant information on Figitumumab for NSCLC is found.\",\n\"answer_choice\": \"B\""]